Clinical Research Directory
Browse clinical research sites, groups, and studies.
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Sponsor: Neurocrine Biosciences
Summary
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-03-31
Completion Date
2027-07
Last Updated
2025-12-01
Healthy Volunteers
No
Conditions
Interventions
NBI-1065845
NBI-1065845 tablets
Placebo
Matching placebo tablets
Locations (10)
Neurocrine Clinical Site
Huntsville, Alabama, United States
Neurocrine Clinical Site
Glendale, California, United States
Neurocrine Clinical Site
Irvine, California, United States
Neurocrine Clinical Site
Miami, Florida, United States
Neurocrine Clinical Site
Tampa, Florida, United States
Neurocrine Clinical Site
Atlanta, Georgia, United States
Neurocrine Clinical Site
Boston, Massachusetts, United States
Neurocrine Clinical Site
Saint Charles, Missouri, United States
Neurocrine Clinical Site
The Bronx, New York, United States
Neurocrine Clinical Site
Mason, Ohio, United States